Severe pediatric autoimmune diseases (AD) have limited therapeutic options. In a recent issue of Nature Medicine, Becilli et al. report a case series where CD19 CAR T cell treatment of pediatric AD patients induced rapid and durable remissions with manageable toxicity. Notably, patients discontinued standard therapies, and benefits persisted even after B cell reconstitution, highlighting the potential of a reset of the immune system that warrants further exploration.
